Purvalanol B

• Supplier: Tocris Bioscience
• Catalog: 1580
• Prices: $209.00, $879.00
• Sizes: 10 mg, 50 mg
• Function Type: Inhibitor
• Cas Number: 212844-54-7
• Chemical Name: (2R)-2-[[6-[(3-Chloro-4-carboxyphenyl)amino]-9-(1-methylethyl)-9H-purin-2-yl]amino]-3-methyl-1-butanol
• Formula: C20H25ClN6O3
• Molecular Weight: 432.91
• Purity: >99 %
• Description: Cyclin-dependent kinase inhibitor. IC 50 values are 6, 6, 9, > 10,000, and 6 nM for cdc2/cyclin B, cdk2/cyclin A, cdk2/cyclin E, cdk4/cyclin D1 and cdk5-p35 respectively. Selective over a range of other protein kinases (IC 50 > 10,000 nM). Shown to have antiproliferative properties, mediated by p42/p44 MAPK.

Product References

Exploiting chemical libraries, structure, and genomics in the search for kinase - Exploiting chemical libraries, structure, and genomics in the search for kinase

Gray NS, Wodicka L, Thunnissen AM, Norman TC, Kwon S, Espinoza FH, Morgan DO, Barnes G, LeClerc S, Meijer L, Kim SH, Lockhart DJ, Schultz PG. Science. 1998 Jul 24;281(5376):533-8.

ATP-site directed inhibitors of cyclin-dependent kinases. - ATP-site directed inhibitors of cyclin-dependent kinases.

Gray N, Detivaud L, Doerig C, Meijer L. Curr Med Chem. 1999 Sep;6(9):859-75.

p42/p44 MAPKs are intracellular targets of the CDK inhibitor purvalanol. - p42/p44 MAPKs are intracellular targets of the CDK inhibitor purvalanol.

Knockaert M, Lenormand P, Gray N, Schultz P, Pouyssegur J, Meijer L. Oncogene. 2002 Sep 19;21(42):6413-24.